New psoriasis drug faces off against cosentyx in major trial
NCT ID NCT06630559
First seen Feb 25, 2026 · Last updated May 14, 2026 · Updated 11 times
Summary
This study tests a new medicine called CT-P55 against the approved drug Cosentyx in 153 adults with moderate to severe plaque psoriasis. The goal is to see if CT-P55 works just as well and is as safe. Participants will receive either CT-P55 or Cosentyx, and doctors will measure changes in skin symptoms over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rheumatology Clinic NZOZ Lecznica MAK-MED s.c.
Nadarzyn, Poland
Conditions
Explore the condition pages connected to this study.